clinical trial

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

An updated analysis finds the SARS-CoV-2 vaccine from Pfizer and BioNTech to have a 95 percent efficacy.

Early data from Moderna suggests its candidate SARS-CoV-2 vaccine is highly effective, writes the Washington Post.

An initial analysis of early data from Pfizer and BioNTech's COVID-19 vaccine trial indicates it is 90 percent effective, the Washington Post reports.

An FDA advisory panel has determined there isn't enough data to gauge whether a new Alzheimer's disease drug works, according to NPR.

Spectrum reports that a clinical trial of a gene therapy for Angelman syndrome is on hold.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.